Larimar Therapeutics, Inc. (LRMR) Misses Q3 EPS by 20c
Tweet
Share
E-mailGet Alerts LRMR Hot Sheet
Join SI Premium – FREE
Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q3 EPS of ($0.61), $0.20 worse than the analyst estimate of ($0.41).
For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bessent: U.S. will enforce 'zero leakage' approach to Iran sanctions
- Freedom Broker Starts Citizens Inc. (CIA) at Buy
- X Financial (XYF) Tops Q2 EPS by 438c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
